| 射血分数保留的心力衰竭合并慢性肾功能不全的研究进展 |
| |
| 引用本文： | 张保华,李慧颖,白永怿,刘宏斌.射血分数保留的心力衰竭合并慢性肾功能不全的研究进展[J].中华老年多器官疾病杂志,2022,21(11):849-853. |
| |
| 作者姓名： | 张保华 李慧颖 白永怿 刘宏斌 |
| |
| 作者单位： | 中国人民解放军总医院第二医学中心 心血管内科,北京100853;中国人民解放军总医院第二医学中心 保健九科,北京100853;中国人民解放军总医院第二医学中心 国家老年疾病临床医学研究中心,北京100853,中国人民解放军总医院第二医学中心 心血管内科,北京100853;中国人民解放军总医院第二医学中心 国家老年疾病临床医学研究中心,北京100853,中国人民解放军总医院第二医学中心 心血管内科,北京100853;中国人民解放军总医院第二医学中心 国家老年疾病临床医学研究中心,北京100853;中国人民解放军总医院第二医学中心 慢性心衰精准医学北京市重点实验室,北京100853,中国人民解放军总医院第二医学中心 心血管内科,北京100853;中国人民解放军总医院第二医学中心 国家老年疾病临床医学研究中心,北京100853;中国人民解放军总医院第二医学中心 慢性心衰精准医学北京市重点实验室,北京100853 |
| |
| 基金项目： | 国家重点研发计划课题(2020YFC2008304); 军队保健专项科研课题(22BJZ26); 国家工信部产业技术基础公共服务平台项目(2020-0103-3-1) |
| |
| 摘 要： | 射血分数保留的心力衰竭(HFpEF)是发病率及死亡率均较高的一种常见疾病,慢性肾功能不全(CKD)是HFpEF患者常见的伴随疾病。HFpEF合并CKD的发病机制尚未完全阐明,HFpEF与CKD常相互影响、交互促进疾病的进展。与单纯HFpEF患者相比,合并CKD的HFpEF患者通常预后较差,且随着肾损伤程度的加重,其死亡风险增加。治疗心力衰竭的基石类药物并不能使HFpEF患者明显获益,然而建议将沙库巴曲缬沙坦等新型抗心力衰竭药物应用于合并轻中度CKD的HFpEF患者。
|
| 关 键 词： | 射血分数保留的心力衰竭 慢性肾功能不全 肾功能恶化 预后 药物治疗 |
| 收稿时间： | 2021/11/24 0:00:00 |
Research progress in heart failure with preserved ejection fraction complicated with chronic kidney disease |
| |
| ZHANG Bao-Hu,LI Hui-Ying,BAI Yong-Yi and LIU Hong-Bin.Research progress in heart failure with preserved ejection fraction complicated with chronic kidney disease[J].Chinrse journal of Multiple Organ Diseases in the Elderly,2022,21(11):849-853. |
| |
| Authors: | ZHANG Bao-Hu LI Hui-Ying BAI Yong-Yi and LIU Hong-Bin |
| |
| Institution: | Department of Cardiology,Beijing 100853, China ;Ninth Department of Health Care, Beijing 100853, China;National Clinical Research Center for Geriatric Diseases,Beijing 100853, China,Department of Cardiology,Beijing 100853, China ;National Clinical Research Center for Geriatric Diseases,Beijing 100853, China,Department of Cardiology,Beijing 100853, China ;National Clinical Research Center for Geriatric Diseases,Beijing 100853, China ;Beijing Key Laboratory of Chronic Heart Failure Precision Medicine, Second Medical Center, Chinese PLA General Hospital, Beijing 100853, China and Department of Cardiology,Beijing 100853, China ;National Clinical Research Center for Geriatric Diseases,Beijing 100853, China ;Beijing Key Laboratory of Chronic Heart Failure Precision Medicine, Second Medical Center, Chinese PLA General Hospital, Beijing 100853, China |
| |
| Abstract: | Heart failure with preserved ejection fraction (HFpEF) is a common disease with high morbidity and mortality, and chronic kidney disease (CKD) is a common comorbidity in HFpEF patients. The pathogenesis of comorbidity of HFpEF and CKD has not been fully elucidated. The bidirectional interactions between HFpEF and CKD may promote their progression. HFpEF patients with comorbid CKD had a poorer prognosis than those with HFpEF alone, and the risk of death increased with the increasing severity of renal injury. HFpEF patients do not benefit significantly from the basic drugs used to treat heart failure. However, it is recommended that new anti-heart failure agents such as sacubitril/valsartan sodium tablets be used in these patients. |
| |
| Keywords: | heart failure with preserved ejection fraction chronic kidney disease worsening renal function prognosis therapeutic strategy This work was supported by National Key Research and Development Projects |
|
| 点击此处可从《中华老年多器官疾病杂志》浏览原始摘要信息 |
| 点击此处可从《中华老年多器官疾病杂志》下载免费的PDF全文 |
|
